KRAS/NRAS (RAS) wild-type, as well as BRAF/HER2 and MAP2K1 (MEK) mutated CRC patients, are sensitive to anti-EGFR therapy [268]. The gene discussed is EGFR; the disease is colorectal carcinoma.